PAVmed (PAVM) Q4 2024 earnings summary

Executive summary

• Completed strategic transformation, including Lucid deconsolidation, debt restructuring, and regained Nasdaq compliance, positioning for long-term sustainability.

• Achieved positive net income of $1.3 million in Q4 2024, a turnaround from a $17.4 million loss in Q4 2023, with EBITDA improving to $1.5 million.

• Lucid Diagnostics and Veris Health achieved record operational and financial milestones, including revenue growth, new partnerships, and expanded clinical evidence.

• Operates as a diversified life sciences company with independently financed subsidiaries under a shared services model.

• Non-GAAP adjusted loss per share narrowed to $(0.06) in Q4 2024 from $(1.33) in Q4 2023.

Financial highlights

• Lucid Diagnostics generated $1.2 million in revenue and achieved a record 4,042 EsoGuard tests in Q4 2024, a 45% quarter-on-quarter increase and 84% year-over-year growth.

• PAVmed reported GAAP net income attributable to common stockholders of $1.3 million, or $0.12 per diluted share for Q4 2024.

• Operating expenses dropped to $5.2 million in Q4 2024 from $17.4 million in Q4 2023, including $0.7 million in stock-based compensation.

• Cash balance increased to $1.2 million at year-end 2024, with pro forma cash including 1Q25 private placement at $3.6 million.

• Senior secured convertible notes reduced by $2.95 million sequentially to $29.1 million.

Outlook and guidance

• Optimistic for Medicare coverage decision for EsoGuard in the first half of 2025.

• Veris implantable monitor regulatory submission expected by end of 2025 or early 2026, with FDA engagement ongoing.

• Cash runway extended past key reimbursement milestones due to debt refinancing and equity offering.

• Veris' pilot program with The Ohio State's James Cancer Hospital extended through April 2025, with a long-term agreement imminent.

• Focused on advancing Veris and PortIO, with expansion to additional cancer centers planned post-implantable clearance.